Drug intelligence / Profile preview

CIN402

Development stage: Unknown
Lead developer: Cincera Therapeutics
Modality: Small Molecules

Overview

CIN402 is a small molecule drug candidate developed by Cincera Therapeutics for the treatment of fibrotic diseases, with its primary active indication being fibrosis. The compound is in the discovery phase and represents a novel drug class with a highly unique and orthogonal mechanism of action for targeting fibrotic pathologies. Specific molecular targets or mechanisms have not been publicly disclosed as of June 2025[1][3][4]. The developer, Cincera Therapeutics, focuses on innovative therapies for unmet medical needs in fibrosis and related conditions.

Beyond the preview

Go deeper on CIN402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIN402.

Explore the full profile